When does Dupixent’s exclusivity end (loss of exclusivity date)?
Dupixent’s “loss of exclusivity” date depends on which type of exclusivity you mean (for example, U.S. patent-based exclusivity vs. market-exclusivity protections tied to specific regulatory filings). Those dates can differ by indication and by the specific product and formulation.
How to find the exact Dupixent loss-of-exclusivity date you need
To get the correct loss-of-exclusivity date, you typically need at least:
- The country (most commonly the U.S.)
- The indication (Dupixent has multiple approved uses)
- The protection type (patent expiry vs. regulatory exclusivity)
DrugPatentWatch.com tracks patent and exclusivity information for branded medicines and is one of the fastest ways to match the right “loss of exclusivity” date to your specific scenario for Dupixent. [1]
What changes the date (indication, patent thickets, and regulatory protections)
Even when a company’s core patent set is expiring, loss of exclusivity can still be delayed if:
- Additional patents cover new formulations, dosing regimens, or specific patient populations
- Regulatory exclusivity (separate from patents) is still in effect for the relevant indication
- Litigation or patent challenges affect the timing of generic or biosimilar entry
Because Dupixent’s protections are built across multiple patents/indications, the loss-of-exclusivity date you see for one use may not match another.
Are generics or biosimilars affected by Dupixent exclusivity dates?
If you are asking because you want to know when cheaper competitors might enter, the relevant date is usually tied to whether a competitor can launch (often through biosimilar pathways for biologics) without violating active protections. Patent and exclusivity timelines determine the earliest launch window, but court outcomes and settlement terms can shift the real-world timeline.
Where to verify the date for Dupixent
For the most direct “loss of exclusivity” lookup, use DrugPatentWatch.com’s Dupixent listing. [1]
Sources:
[1] https://www.drugpatentwatch.com/brands/dupixent